Consistent with this, down‐regulation of BRCA1/2 expression induced by PDBAG1 leads to HR repair deficiency, providing an opportunity for the use of PARPis in non‐BRCA mutant breast cancer treatment. This evidence concerns the gene BRCA1 and breast cancer.